Application of 18F-fluorodeoxyglucose positron emission tomography in diagnosis of malignant diseases

Chin Med Sci J. 2009 Jun;24(2):117-21. doi: 10.1016/s1001-9294(09)60073-0.

Abstract

Objective: To testify the efficacy of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) in the diagnosis of cancer.

Methods: A total of 170 patients with diagnosed cancer or suspicious cancer were enrolled in this study, and underwent 18F-FDG PET. The standard uptake value (SUV) and diameter for each abnormal region in PET images were analyzed. All data were analyzed by SPSS 11.5.

Results: PET scan identified a primary cancer in 45.8% (11/24) patients. The sensitivity and specificity of PET scan in differentiating malignant lesions from benign ones were 78.8% (52/66) and 77.1% (27/35) respectively. Twenty-nine out of 68 (42.6%) lesions were detected earlier by PET than by computed tomography. The SUV of primary cancer was significantly higher than that of metastatic lymph nodes (5.84 +/- 3.12 vs. 3.14 +/- 2.24, P<0.001). And SUV of primary lung cancer was also significantly higher than that of metastatic lung cancer (6.30 +/- 3.01 vs. 2.86 +/- 2.37, P<0.01).

Conclusion: 18F-FDG PET plays a very important role in cancer diagnosis.

Publication types

  • Evaluation Study

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Female
  • Fluorodeoxyglucose F18
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Metastasis
  • Neoplasms / diagnosis*
  • Neoplasms / pathology
  • Neoplasms, Unknown Primary / diagnosis
  • Neoplasms, Unknown Primary / pathology
  • Positron-Emission Tomography / methods*
  • Radiopharmaceuticals / metabolism*
  • Retrospective Studies
  • Sensitivity and Specificity
  • Young Adult

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18